Incretin Atlas › Molecules › Albiglutide
Albiglutide
GLP-1 · s.c. · GSK
Summary
- Also known as
- Tanzeum (withdrawn)
- Mechanism
- GLP-1
- Route
- s.c.
- Company
- GSK
- Highest development stage
- —
- Status (as of data cut)
- Withdrawn from market (2018) despite positive CVOT verify
- Next milestone
- —
Trial arms: weight, HbA1c and tolerability
No trial arms with extracted efficacy or tolerability data yet.
Outcome trials
Cardiovascular and kidney outcome trials
Harmony Outcomes albiglutide 30–50 mg vs placebo · T2D + CVD · n = 9463 · 2018 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| 3-point MACE primary First occurrence of CV death, non-fatal MI, or non-fatal stroke | 0.78 | 0.68–0.90 | 338 vs 428 | verified |
| 4-point MACE Expanded composite: CV death, non-fatal MI, non-fatal stroke, or urgent coronary revascularisation for unstable angina | 0.78 | 0.69–0.90 | 373 vs 468 | verified |
| Cardiovascular death Death from cardiovascular causes | 0.93 | 0.73–1.19 | 122 vs 130 | verified |
| All-cause death Death from any cause | 0.95 | 0.79–1.16 | 196 vs 205 | verified |
| Myocardial infarction Fatal or non-fatal myocardial infarction | 0.75 | 0.61–0.90 | 181 vs 240 | verified |
| Stroke Fatal or non-fatal stroke | 0.86 | 0.66–1.14 | 94 vs 108 | verified |
| CV death or worsening HF Composite of death from cardiovascular causes or hospital admission for heart failure | 0.85 | 0.70–1.04 | 188 vs 218 | verified |
| Expanded MACE (MACE + revasc. + UA) Expanded composite: death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke, or urgent coronary revascularisation for unstable angina | 0.78 | 0.69–0.90 | 373 vs 468 | verified |
Verbatim quotes (8)
- 3-point MACE · Summary, Findings; Table 2
The primary composite outcome occurred in 338 (7%) of 4731 patients ... and in 428 (9%) of 4732 patients ... (hazard ratio 0·78, 95% CI 0·68–0·90)
- 4-point MACE · Table 2
Expanded composite outcome‡ 373 (8%) 5·06 468 (10%) 6·45 0·78 (0·69–0·90) 0·0005
- Cardiovascular death · Table 2
Death from cardiovascular causes 122 (3%) 1·61 130 (3%) 1·72 0·93 (0·73–1·19) 0·578
- All-cause death · Table 2
Death from any cause 196 (4%) 2·44 205 (4%) 2·56 0·95 (0·79–1·16) 0·644
- Myocardial infarction · Table 2
Fatal or non-fatal myocardial infarction 181 (4%) 2·43 240 (5%) 3·26 0·75 (0·61–0·90) 0·003
- Stroke · Table 2
Fatal or non-fatal stroke 94 (2%) 1·25 108 (2%) 1·45 0·86 (0·66–1·14) 0·300
- CV death or worsening HF · Table 2
Composite of death from cardiovascular causes or hospital admission for heart failure 188 (4%) 2·49 218 (5%) 2·92 0·85 (0·70–1·04) 0·113
- Expanded MACE (MACE + revasc. + UA) · Table 2: Primary and secondary cardiovascular outcomes (footnote ‡)
Expanded composite outcome‡ 373 (8%) 5·06 468 (10%) 6·45 0·78 (0·69–0·90) 0·0005
Registered trials (1)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| Harmony Outcomes Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus | CV outcomes | Phase 4 | completed | 2015-07 → 2018-02 | 9463 | MACE HR 0.78 (0.68–0.90) | NCT02465515 |
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: Albiglutide. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/albiglutide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.